Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer

Koike Folgueira, Maria Aparecida Azevedo, Carraro, Dirce Maria, Brentani, Helena, da Costa Patrão, Diogo Ferreira, Barbosa, Edson Mantovani, Netto, Mário Mourão, Caldeira, José Roberto Fígaro, Katayama, Maria Lucia Hirata, Soares, Fernando Augusto, Oliveira, Célia Tosello, Reis, Luiz Fernando Lima, Kaiano, Jane Haruko Lima, Camargo, Luiz Paulo, Vêncio, Ricardo Zorzetto Nicoliello, Snitcovsky, Igor Moysés Longo, Makdissi, Fabiana Baroni Alves, da Silva e Silva, Paulo José, Góes, João Carlos Guedes Sampaio, Brentani, Maria Mitzi · 2005 · Clinical Cancer Research

Abstract

Purpose: This study was designed to identify genes that could predict response to doxorubicin-based primary chemotherapy in breast cancer patients. Experimental Design: Biopsy samples were obtained before primary treatment with doxorubicin and cyclophosphamide. RNA was extracted and amplified and gene expression was analyzed using cDNA microarrays. Results: Response to chemotherapy was evaluated in 51 patients, and based on Response Evaluation Criteria in Solid Tumors guidelines, 42 patients, who presented at least a partial response (≥30% reduction in tumor dimension), were classified as responsive. Gene profile of samples, divided into training set (n = 38) and independent validation set (n = 13), were at first analyzed against a cDNA microarray platform containing 692 genes. Unsupervised clustering could not separate responders from nonresponders. A classifier was identified comprising EMILIN1, FAM14B, and PBEF, which however could not correctly classify samples included in the validation set. Our next step was to analyze gene profile in a more comprehensive cDNA microarray platform, containing 4,608 open reading frame expressed sequence tags. Seven samples of the initial training set (all responder patients) could not be analyzed. Unsupervised clustering could correctly group all the resistant samples as well as at least 85% of the sensitive samples. Additionally, a classifier, including PRSS11, MTSS1, and CLPTM1, could correctly distinguish 95.4% of the 44 samples analyzed, with only two misclassifications, one sensitive sample and one resistant tumor. The robustness of this classifier is 2.5 greater than the first one. Conclusion: A trio of genes might potentially distinguish doxorubicin-responsive from nonresponsive tumors, but further validation by a larger number of samples is still needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-04-0548

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 235

Metadata

Authors
Koike Folgueira, M. A. A., Carraro, D. M., Brentani, H., da Costa Patrão, D. F., Barbosa, E. M., Netto, M. M., Caldeira, J. R. F., Katayama, M. L. H., Soares, F. A., Oliveira, C. T., Reis, L. F. L., Kaiano, J. H. L., Camargo, L. P., Vêncio, R. Z. N., Snitcovsky, I. M. L., Makdissi, F. B. A., da Silva e Silva, P. J., Góes, J. C. G. S., & Brentani, M. M.
Venue
Clinical Cancer Research
Published
2005-10-15
Volume
11
Issue
20
Pages
7434-7443
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2139336758
Cited by
235
References
3
FWCI
8.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0548
The paper
Koike Folgueira, M. A. A., Carraro, D. M., Brentani, H., da Costa Patrão, D. F., Barbosa, E. M., Netto, M. M., Caldeira, J. R. F., Katayama, M. L. H., Soares, F. A., Oliveira, C. T., Reis, L. F. L., Kaiano, J. H. L., Camargo, L. P., Vêncio, R. Z. N., Snitcovsky, I. M. L., Makdissi, F. B. A., da Silva e Silva, P. J., Góes, J. C. G. S., & Brentani, M. M. (2005). Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0548

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.